In this report of outpatients with MDD, we found that levels of S100B at baseline predicted persistently elevated levels of anhedonia with escitalopram monotherapy but not with bupropion plus escitalopram or venlafaxine plus mirtazapine. Here, S100B is linked to major depressive disorder.